Details of the Drug

General Information of Drug (ID: DMIMA4V)

Drug Name
BPX-501
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 1/2 [1]
Acute myeloid leukaemia 2A60 Phase 1/2 [1]
Hematopoietic stem cell transplantation QB63 Phase 1/2 [2]
Immunodeficiency 4A00-4A85 Phase 1/2 [3]
Osteoporosis FB83.0 Phase 1/2 [4]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
⏷ Show the Full List of Indication(s)
Cross-matching ID
TTD ID
D06LYI
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cells (T-cells) TTXQYT6 NOUNIPROTAC Immunomodulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health.